MCID: END038
MIFTS: 42

Endocrine Pancreas Disease

Categories: Endocrine diseases

Aliases & Classifications for Endocrine Pancreas Disease

MalaCards integrated aliases for Endocrine Pancreas Disease:

Name: Endocrine Pancreas Disease 12 14
Disorder of Endocrine Pancreas 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1428
ICD10 33 E16
ICD9CM 35 251
UMLS 69 C0154189

Summaries for Endocrine Pancreas Disease

MalaCards based summary : Endocrine Pancreas Disease, also known as disorder of endocrine pancreas, is related to functioning pituitary adenoma and cleft lip and palate malrotation cardiopathy. An important gene associated with Endocrine Pancreas Disease is INS (Insulin), and among its related pathways/superpathways are Metabolism and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Secretin and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and lung, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Endocrine Pancreas Disease

Diseases related to Endocrine Pancreas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
id Related Disease Score Top Affiliating Genes
1 functioning pituitary adenoma 10.9 POMC SST
2 cleft lip and palate malrotation cardiopathy 10.8 LEP POMC
3 selenium poisoning 10.8 IGF1 INS
4 cutis laxa 10.8 INS POMC
5 african histoplasmosis 10.8 POMC SST
6 diabetes mellitus, transient neonatal, 3 10.8 ABCC8 KCNJ11
7 ulcerative blepharitis 10.8 IGF1 INS POMC
8 prolactin producing pituitary tumor 10.7 IGF1 POMC SST
9 acute myocarditis 10.7 INS POMC SST
10 diabetes mellitus, permanent neonatal 10.7 ABCC8 GCK
11 fibrolamellar carcinoma 10.7 IGF1 INS POMC
12 cardiovascular organ benign neoplasm 10.7 IGF1 POMC SST
13 oxyphilic adenoma 10.7 IGF1 IRS1
14 algoneurodystrophy 10.7 IGF1 IGF2 INS
15 capillary lymphangioma 10.7 IGF1 INS POMC
16 pelvic muscle wasting 10.7 IGF1 INS POMC
17 pericardial tuberculosis 10.7 IGF1 IGF2 INS
18 kartagener syndrome 10.7 IGF2 INS SST
19 pandas 10.7 INS SST
20 porokeratosis 10.7 IGF1 INS LEP
21 psychogenic movement 10.7 IGF1 POMC SST
22 vestibular gland benign neoplasm 10.6 IGF1 POMC SST
23 intestinal volvulus 10.6 GIP INS SST
24 nephronophthisis 19 10.6 ABCC8 INS KCNJ11
25 allergic asthma 10.6 IGF1 INS POMC
26 adrenal cortex disease 10.6 LEP POMC SST
27 alpha-methylacyl-coa racemase deficiency 10.6 IGF1 POMC SST
28 alstrom syndrome 10.6 INS KCNJ11 LEP
29 pituitary adenoma, acth-secreting 10.6 IGF1 POMC SST
30 retinitis pigmentosa 68 10.6 ABCC8 G6PC INS
31 hemoglobin zurich 10.6 ABCC8 IGF2 KCNJ11
32 myh-9 related disease 10.6 INS LEP SLC2A4
33 perinephritis 10.6 ABCC8 G6PC INS
34 usher syndrome, type 1f 10.6 IGF1 POMC SST
35 protein s deficiency 10.6 IGF1 INS POMC SST
36 uterine ligament clear cell adenocarcinoma 10.5 IGF1 INS POMC SST
37 male reproductive organ benign neoplasm 10.5 IGF1 INS POMC SST
38 breast fibroadenoma 10.5 IGF2 INS
39 atrial fibrillation, familial, 12 10.5 ABCC8 KCNJ11
40 acquired hypoprothrombinemia 10.5 ADIPOQ LEP
41 cardiomyopathy, dilated, 1jj 10.5 GCG INS
42 glomerulosclerosis, focal segmental, 1 10.5 IGF1 INS IRS1
43 writing disorder 10.5 ABCC8 GCK KCNJ11
44 mononeuritis of upper limb and mononeuritis multiplex 10.5 IGF1 SST
45 skin meningioma 10.5 INS LEP SST
46 fetal parvovirus syndrome 10.5 IGF1 IGF2 INS LEP
47 repetitive stress injuries 10.5 INS SST
48 leigh syndrome with leukodystrophy 10.4 ADIPOQ LEP
49 nonsyndromic hereditary sensorineural hearing loss 10.4 ADIPOQ INS LEP
50 mucinoses 10.4 ADIPOQ INS LEP

Graphical network of the top 20 diseases related to Endocrine Pancreas Disease:



Diseases related to Endocrine Pancreas Disease

Symptoms & Phenotypes for Endocrine Pancreas Disease

MGI Mouse Phenotypes related to Endocrine Pancreas Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.33 ADIPOQ DPP4 G6PC GCK GIP GLP1R
2 homeostasis/metabolism MP:0005376 10.3 GIP GLP1R IGF1 IGF2 INS IRS1
3 endocrine/exocrine gland MP:0005379 10.25 IGF2 INS IRS1 KCNJ11 LEP POMC
4 behavior/neurological MP:0005386 10.2 PPY SLC5A2 SST ADIPOQ G6PC GLP1R
5 adipose tissue MP:0005375 10.18 ADIPOQ GLP1R IGF1 INS IRS1 KCNJ11
6 liver/biliary system MP:0005370 9.97 ADIPOQ G6PC GCK IGF2 INS IRS1
7 muscle MP:0005369 9.86 ADIPOQ IGF1 IGF2 INS IRS1 KCNJ11
8 no phenotypic analysis MP:0003012 9.7 ABCC8 IGF2 INS KCNJ11 POMC SLC5A2
9 renal/urinary system MP:0005367 9.61 POMC SLC5A2 ADIPOQ G6PC GCK IGF1
10 skeleton MP:0005390 9.32 ADIPOQ G6PC IGF1 IGF2 INS IRS1

Drugs & Therapeutics for Endocrine Pancreas Disease

Drugs for Endocrine Pancreas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 669)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
2
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
3
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
4
Saxagliptin Approved Phase 4,Phase 3 361442-04-8 11243969
5
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
9
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
10
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
11
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
12
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
17
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
18
Empagliflozin Approved Phase 4 864070-44-0
19
Linagliptin Approved Phase 4 668270-12-0 10096344
20
Dexlansoprazole Approved Phase 4 138530-94-6, 103577-45-3 9578005
21
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
22
Etomidate Approved Phase 4 33125-97-2 36339 667484
23
Meperidine Approved Phase 4 57-42-1 4058
24
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
25
Glimepiride Approved Phase 4 93479-97-1 3476
26
Insulin Glargine Approved Phase 4 160337-95-1
27
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
28
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
29
Nicotine Approved Phase 4 54-11-5 942 89594
30
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6
31
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
32
Iron Approved Phase 4,Phase 1 7439-89-6 23925
33
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
34
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
35
Thrombin Approved Phase 4,Phase 2
36
Desflurane Approved Phase 4 57041-67-5 42113
37
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
38
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
39
Tegafur Approved Phase 4,Phase 2,Phase 1 17902-23-7 5386
40
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
41 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
42
Butyric Acid Experimental Phase 4,Phase 1,Phase 2 107-92-6 264
43 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
44 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 gastric inhibitory polypeptide Phase 4
49 glucagon Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Glucagon-Like Peptide 1 Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1874)

id Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
3 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
4 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
5 Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology Completed NCT02401880 Phase 4 Linagliptin;Empagliflozin
6 Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function Completed NCT02304081 Phase 4 Saxagliptin;Placebo for Saxagliptin
7 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
8 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
9 Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation Completed NCT01668485 Phase 4
10 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
11 Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil) Completed NCT00642915 Phase 4 Lantus, Amaryl
12 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
13 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
14 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
15 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
16 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
17 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
18 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
19 Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes Recruiting NCT03004612 Phase 4 Linagliptin + metformin
20 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
21 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
22 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
23 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
24 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
25 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
26 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
27 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
28 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
29 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Active, not recruiting NCT02238847 Phase 4
30 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
31 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
32 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Not yet recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
33 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
34 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
35 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
36 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
37 A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Withdrawn NCT02009410 Phase 4 Creon;Creon 25000 matching Placebo
38 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
39 Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation Unknown status NCT01817959 Phase 3 Reparixin;Placebo
40 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
41 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
42 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
43 A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Unknown status NCT00789633 Phase 3 masitinib (AB1010);placebo
44 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3 Gemcitabine;Curcumin;Celebrex
45 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
46 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
47 PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen Unknown status NCT00088660 Phase 3
48 Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Unknown status NCT02311439 Phase 2, Phase 3 FOLFIRINOX + CRT
49 Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer Unknown status NCT02079623 Phase 3
50 Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan

Search NIH Clinical Center for Endocrine Pancreas Disease

Genetic Tests for Endocrine Pancreas Disease

Anatomical Context for Endocrine Pancreas Disease

MalaCards organs/tissues related to Endocrine Pancreas Disease:

39
Pancreas, Liver, Lung, Kidney, Breast, Pancreatic Islet, Colon

Publications for Endocrine Pancreas Disease

Variations for Endocrine Pancreas Disease

Expression for Endocrine Pancreas Disease

Search GEO for disease gene expression data for Endocrine Pancreas Disease.

Pathways for Endocrine Pancreas Disease

Pathways related to Endocrine Pancreas Disease according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 ABCC8 ADIPOQ G6PC GCG GCK GLP1R
2
Show member pathways
13.3 ABCC8 G6PC GCK KCNJ11 SLC2A4 SLC5A2
3
Show member pathways
12.83 G6PC GCK IGF1 INS IRS1 SLC2A4
4
Show member pathways
12.79 G6PC GCK SLC2A4 SLC5A2 SLC5A4
5
Show member pathways
12.71 ADIPOQ INS IRS1 LEP SLC2A4
6 12.48 ADIPOQ GCG INS IRS1 SLC2A4 SLC5A2
7
Show member pathways
12.39 GCK INS IRS1 LEP
8
Show member pathways
12.39 ADIPOQ G6PC IGF1 INS IRS1 LEP
9
Show member pathways
12.35 ABCC8 ADIPOQ GCG GLP1R INS KCNJ11
10
Show member pathways
12.31 ABCC8 GCG GCK GIP GLP1R INS
11
Show member pathways
12.14 INS IRS1 LEP SLC2A4
12
Show member pathways
12.07 ADIPOQ IGF1 INS IRS1
13
Show member pathways
12.06 G6PC IGF1 INS IRS1 SLC2A4
14 12.04 GCG GIP GLP1R POMC
15 12 ADIPOQ IGF1 INS IRS1 LEP SLC2A4
16
Show member pathways
11.96 DPP4 GCG GIP IGF1 INS LEP
17
Show member pathways
11.9 G6PC INS IRS1 SLC2A4
18
Show member pathways
11.89 G6PC GCK SLC2A4 SLC5A2 SLC5A4
19 11.86 ADIPOQ IGF1 INS LEP SLC2A4
20 11.83 G6PC GCG GCK
21
Show member pathways
11.6 DPP4 GCG GIP LEP
22 11.51 IGF1 IGF2 INS
23 11.47 INS IRS1 LEP
24 11.44 ABCC8 IRS1 KCNJ11 LEP SLC2A4
25 11.31 IGF1 INS IRS1
26 11.3 ABCC8 G6PC GCK INS KCNJ11
27 11.27 ADIPOQ G6PC IRS1 LEP POMC SLC2A4
28
Show member pathways
11.15 ABCC8 ADIPOQ GCK INS IRS1 KCNJ11
29 11.1 ADIPOQ IRS1 LEP SLC2A4
30 10.84 INS SLC2A4

GO Terms for Endocrine Pancreas Disease

Cellular components related to Endocrine Pancreas Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ADIPOQ DPP4 GCG GIP IGF1 IGF2
2 sarcolemma GO:0042383 9.5 ABCC8 KCNJ11 SLC2A4
3 secretory granule lumen GO:0034774 9.46 GCG GIP INS POMC
4 extracellular space GO:0005615 9.32 ADIPOQ GCG GIP IGF1 IGF2 INS
5 ATP-sensitive potassium channel complex GO:0008282 9.26 ABCC8 KCNJ11

Biological processes related to Endocrine Pancreas Disease according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 ABCC8 ADIPOQ GIP KCNJ11 SST
2 carbohydrate metabolic process GO:0005975 9.91 GCK IGF2 INS SLC2A4 SLC5A2
3 female pregnancy GO:0007565 9.83 ABCC8 GIP LEP
4 positive regulation of protein kinase B signaling GO:0051897 9.82 IGF2 INS LEP
5 response to nutrient GO:0007584 9.81 ADIPOQ LEP SST
6 insulin receptor signaling pathway GO:0008286 9.8 IGF2 INS IRS1
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 ADIPOQ IGF1 IGF2 INS
8 response to insulin GO:0032868 9.78 ABCC8 IRS1 LEP
9 positive regulation of MAPK cascade GO:0043410 9.78 IGF1 IGF2 INS LEP
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 IGF1 INS LEP
11 response to nutrient levels GO:0031667 9.77 ADIPOQ GIP LEP
12 carbohydrate transport GO:0008643 9.74 SLC2A4 SLC5A2 SLC5A4
13 cellular response to insulin stimulus GO:0032869 9.73 ADIPOQ GCK IRS1 SLC2A4
14 glucose metabolic process GO:0006006 9.73 ADIPOQ GCK IGF2 INS KCNJ11 LEP
15 negative regulation of insulin secretion GO:0046676 9.71 ABCC8 IRS1 KCNJ11
16 positive regulation of mitotic nuclear division GO:0045840 9.7 IGF1 IGF2 INS
17 positive regulation of glucose import GO:0046326 9.67 ADIPOQ IGF1 INS IRS1
18 cellular glucose homeostasis GO:0001678 9.65 ABCC8 GCK
19 insulin-like growth factor receptor signaling pathway GO:0048009 9.64 IGF1 IRS1
20 response to acidic pH GO:0010447 9.64 GIP SST
21 glucose transmembrane transport GO:1904659 9.63 SLC2A4 SLC5A2 SLC5A4
22 cellular response to leptin stimulus GO:0044320 9.62 GCK LEP
23 glucose 6-phosphate metabolic process GO:0051156 9.62 G6PC GCK
24 positive regulation of insulin receptor signaling pathway GO:0046628 9.62 IGF2 INS IRS1 LEP
25 regulation of appetite GO:0032098 9.61 POMC PPY
26 bone mineralization involved in bone maturation GO:0035630 9.58 IGF1 LEP
27 negative regulation of gluconeogenesis GO:0045721 9.58 ADIPOQ GCK INS
28 positive regulation of glycogen (starch) synthase activity GO:2000467 9.56 ADIPOQ IGF2
29 positive regulation of glycogen biosynthetic process GO:0045725 9.55 GCK IGF1 IGF2 INS IRS1
30 glucose homeostasis GO:0042593 9.5 ADIPOQ G6PC GCK INS IRS1 LEP
31 regulation of insulin secretion GO:0050796 9.23 ABCC8 DPP4 GCG GCK GIP GLP1R
32 positive regulation of cell proliferation GO:0008284 10.02 DPP4 IGF1 IGF2 INS IRS1 LEP

Molecular functions related to Endocrine Pancreas Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.73 ADIPOQ DPP4 GCG LEP POMC PPY
2 insulin receptor binding GO:0005158 9.46 IGF1 IGF2 INS IRS1
3 glucose:sodium symporter activity GO:0005412 9.37 SLC5A2 SLC5A4
4 ATP-activated inward rectifier potassium channel activity GO:0015272 9.32 ABCC8 KCNJ11
5 hormone activity GO:0005179 9.32 ADIPOQ GCG GIP IGF1 IGF2 INS
6 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 IGF2 INS IRS1

Sources for Endocrine Pancreas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....